First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses

Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect

(2011) Annika Braun et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

TNF-α-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells

(2009) Irina Treede et al.   BMC GASTROENTEROLOGY

Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis

(2009) Annika Braun et al.   INFLAMMATORY BOWEL DISEASES

Serious Events with Infliximab in Patients with Inflammatory Bowel Disease

(2008) Hilbert S de Vries et al.   DRUG SAFETY

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

(2008) H Fidder et al.   GUT

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis

Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches

(2007) Peter Lane   PHARMACEUTICAL STATISTICS